Atara Biotherapeutics Faces Securities Fraud Class Action Over Failed Drug Candidate
Class action lawsuit filed against $ATRA over alleged misstatements on tabelecleucel prospects. FDA rejected drug twice; stock crashed 40-57% post-announcements.
ATRAsecurities fraudclass action lawsuit